The Circadian Clock in Cancer Development and Therapy - Progress in Molecular Biology and Translational Science - page 278

389. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommen-
dations. Ann N Y Acad Sci . Oct 2012;1271:37-43.
390. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: les-
sons learned from early clinical trials. Nat Rev Clin Oncol . 2013;10(3):143-153.
391. Diaz-Meco MT, Moscat J. The atypical PKCs in inflammation: NF-kappaB and
beyond. Immunol Rev . Mar 2012;246(1):154-167.
392. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/
STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leu-
kemogenesis. Leukemia . Feb 2004;18(2):189-218.
393. Dobrovolna J, Chinenov Y, Kennedy MA, Liu B, Rogatsky I. Glucocorticoid-
dependent phosphorylation of the transcriptional coregulator GRIP1. Mol Cell Biol .
Feb 2012;32(4):730-739.
394. Dahlman-Wright K, Qiao Y, Jonsson P, Gustafsson JA, Williams C, Zhao C. Interplay
between AP-1 and estrogen receptor alpha in regulating gene expression and prolifer-
ation networks in breast cancer cells. Carcinogenesis . Sep 2012;33(9):1684-1691.
395. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer .
2003;3(5):350-361.
396. Rhind N, Russell P. Signaling pathways that regulate cell division. Cold Spring Harb
Perspect Biol. 2012;4(10).
397. Gallego M, Virshup DM. Post-translational modifications regulate the ticking of the
circadian clock. Nat Rev Mol Cell Biol . 2007;8(2):139-148.
398. Cao R, Obrietan K. mTOR signaling and entrainment of the mammalian circadian
clock. Mol Cell Pharmacol . 2010;2(4):125-130.
399. Volden PA, Conzen SD. The influence of glucocorticoid signaling on tumor progres-
sion. Brain Behav Immun . 2013;30(Suppl):S26-S31.
400. Cole SW. Nervous system regulation of the cancer genome. Brain Behav Immun .
2012;30:S10-S18.
401. Anand P, Kunnumakkara AB, Sundaram C, et al. Cancer is a preventable disease that
requires major lifestyle changes. Pharm Res . 2008;25(9):2097-2116.
402. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev
Immunol . 2004;22:329-360.
403. Mlecnik B, Bindea G, Pages F, Galon J. Tumor immunosurveillance in human cancers.
Cancer Metastasis Rev . 2011;30(1):5-12.
404. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities indepen-
dently control tumor initiation, growth, and metastasis. Blood . 2001;97(1):192-197.
405. Street SE, Trapani JA, MacGregor D, SmythMJ. Suppression of lymphoma and epithelial
malignancies effected by interferon gamma. J Exp Med . 2002;196(1): 129-134.
406. van den Broek ME, Kagi D, Ossendorp F, et al. Decreased tumor surveillance in
perforin-deficient mice. J Exp Med . 1996;184(5):1781-1790.
407. Shinkai Y, Rathbun G, LamKP, et al. RAG-2-deficient mice lack mature lymphocytes
owing to inability to initiate V(D)J rearrangement. Cell . 1992;68(5):855-867.
408. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary
tumour development and shape tumour immunogenicity. Nature . 2001;410

(6832):1107-1111.
409. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of
“tumor escape” phenotypes. Nat Immunol . 2002;3(11):999-1005.
410. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature .
2011;480(7378):480-489.
411. Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat
Rev Immunol . 2013;13(3):190-198.
412. Bellinger DL, Millar BA, Perez S, et al. Sympathetic modulation of immunity: rele-
vance to disease. Cell Immunol . 2008;252(1-2):27-56.